TRIFERON

Serial Number 75741619
606

Registration Progress

Application Filed
Jun 25, 1999
Under Examination
Nov 13, 2001
Approved for Publication
Aug 1, 2001
Published for Opposition
Aug 21, 2001
Registered

Trademark Image

TRIFERON

Basic Information

Serial Number
75741619
Filing Date
June 25, 1999
Published for Opposition
August 21, 2001
Abandonment Date
May 14, 2003
Drawing Code
1000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
May 14, 2003
Classes
005

Rights Holder

Human Genome Sciences, Inc.

03
Address
9410 Key West Avenue
Rockville, MD 20850

Ownership History

Human Genome Sciences, Inc.

Original Applicant
03
Rockville, MD

Human Genome Sciences, Inc.

Owner at Publication
03
Rockville, MD

Legal Representation

Attorney
Tracy-Gene G. Durkin

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

16 events
Date Code Type Description Documents
Jan 8, 2004 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jan 13, 2003 EX2G S SOU EXTENSION 2 GRANTED Loading...
Nov 13, 2002 MAIL I PAPER RECEIVED Loading...
Nov 13, 2002 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 25, 2002 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 16, 2002 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 13, 2001 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 21, 2001 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 1, 2001 NPUB O NOTICE OF PUBLICATION Loading...
Apr 1, 2001 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 13, 2000 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 19, 2000 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 28, 2000 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Sep 29, 1999 CNRT F NON-FINAL ACTION MAILED Loading...
Sep 29, 1999 REIN O REINSTATED Loading...
Sep 24, 1999 DOCK D ASSIGNED TO EXAMINER Loading...

Detailed Classifications

Class 005
Human interferon and pharmaceutical preparations containing interferon for the treatment of various (1) viral diseases, autoimmune diseases, and immunological disorders, namely, multiple sclerosis, HIV-AIDS, Hepatitis B and C, cancer, herpes, respiratory syncytial virus, pancricephalitis, and mycosis fungiodes; (2) cancers, namely, myclogenous leukemia, melanoina, renal carcinoma, colorectal cancer, cutaneous T cell lymphorna, myelodysplastic syndrome, glioma, head and neck cancer, breast cancer, gastric cancer and anti-cancer vaccine therapy; and (3) inflammatory responses, namely, infection and wound healing
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005